Advertisement
Organisation › Details
M Ventures (Merck Ventures B.V., MV)
M Ventures is the strategic, corporate venture capital arm of Merck. From its headquarters in the Netherlands and offices in Germany, USA and Israel, M Ventures invests globally in transformational ideas driven by innovative entrepreneurs. Taking an active role in its portfolio companies, M Ventures teams up with management teams and co-investors to translate scientific discoveries into commercial success. M Ventures focuses on identifying and financing novel solutions to some of the most difficult challenges, through company creation and equity investments in fields that will impact the vitality and sustainability of Merck's current and future businesses. *
Start | 2016-06-08 renamed | |
Group | Merck (DE) (Group) | |
Predecessor | MS Ventures (Merck Serono Ventures) | |
Industry | venture capital | |
Industry 2 | BIOTECH | |
Person | Liechtenstein, Therese Maria (Merck (DE) 202004 at M Ventures) | |
Person 2 | Autret, Arnaud (Illumina 202205– Head of European Operations at Illumina Ventures before M Ventures) | |
Region | Amsterdam | |
Country | Netherlands | |
Street | 84a Gustav Mahlerplein Ito Toren, 13th floor | |
City | 1082 MA Amsterdam | |
Address record changed: 2024-01-05 | ||
Basic data | Employees | n. a. |
Currency | EUR | |
Annual sales | 300,000,000 (capital, committed 2016-06-08) | |
* Document for »About Section«: Iktos SAS. (3/9/23). "Press Release: Iktos Raises € 15.5m Series A Round to Expand Its Artificial Intelligence-based Drug Discovery Technologies and Solutions". Paris & Lausanne. | ||
Record changed: 2024-02-12 |
Advertisement
More documents for Merck (DE) (Group)
- [1] Caris Life Sciences Inc.. (4/4/24). "Press Release: Caris Life Sciences Announces Partnership with Merck KGaA, Darmstadt, Germany to Discover Novel Cancer Targets and Accelerate First-In-Class Antibody Drug Conjugate Development". Irving, TX....
- [2] BioGeneration Ventures B.V.. (4/2/24). "Press Release: BGV Appoints Peter Halle, PhD as Venture Partner". Amsterdam....
- [3] C4 Therapeutics, Inc.. (3/4/24). "Press Release: C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins". Watertown, MA....
- [4] Precirix N.V.. (2/29/24). "Press Release: Tom Plitz Commences Role as Chief Executive Officer of Precirix". Brussels....
- [5] Merck KGaA. (1/4/24). "Press Release: Merck Expands Colorectal Cancer Portfolio Through Licensing Agreement with Inspirna [Not intended for UK-, US- or Canada-based media]". Darmstadt....
- [6] ITM Isotope Technologies Munich SE. (12/14/23). "Press Release: ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development and Commercialization of Folate-Based Radiotheranostics". Garching....
- [7] Merck KGaA. (12/4/23). "Press Release: Merck Strengthens Oncology Portfolio through Commercialization Agreement With Abbisko for Phase III Asset, Pimicotinib [Not intended for UK-, US- or Canada-based media]". Darmstadt....
- [8] Merck KGaA. (11/21/23). "Press Release: Merck Expands Newest Biologics Testing Center in Shanghai". Shanghai....
- [9] Merck KGaA. (11/14/23). "Press Release: Merck Announces Plans for New U.S. Healthcare Headquarters in Boston’s Seaport District [Not intended for US-based media]". Darmstadt....
- [10] Merck KGaA. (10/30/23). "Press Release: Merck Strengthens Oncology Pipeline Through Strategic Partnership with Hengrui for Next-Generation Selective PARP1 Inhibitor and Antibody-Drug Conjugate [Not intended for US-, Canada- or UK-based media]". Darmstadt...
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top